Synthesis of Non-GMP Small Molecules

非 GMP 小分子的合成

• 批准号: 8328348
• 负责人: MARY TANGA
• 金额: $ 10万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-29 至 2012-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8328348
• 关键词: Antineoplastic Agents; Biological; Biological Factors; Chemicals; Chemistry; Contracts; Development; Developmental Therapeutics Program; Division of Cancer Treatment and Diagnosis; Evaluation; Funding; Heterocyclic Steroids; Lead; Literature; Malignant Neoplasms; Methodology; Methods; Mission; Pharmacodynamics; Property; Recommendation; Series; Staging; United States National Institutes of Health; Work; analog; cancer diagnosis; cancer therapy; chemical synthesis; drug development; improved; novel; programs; small molecule; steroid analog

The addition of ARRA funds will be utilized for synthesis and acquisition of the anticancer agent known in the literature; those can be further studied in the NCI's anticancer program. The mission of the Developmental Therapeutics Program (DTP) is the development of novel synthetic and characterized natural products as potential anti-cancer agents. Towards this mission the contract will be devoted to the synthesis of small molecules needed by the various programs of the Division of Cancer Treatment and Diagnosis (DCTD), and other NIH divisions. This contract will provide essential synthesis support for the early stages of the drug development program. The small molecules assigned for the syntheses encompass a variety of structural classes; e.g., carbocyclics, heterocyclics, steroid analogs, and natural products. They originate from the NExT initiative of the DCTD, Biological Evaluation Committee (BEC), and other NCI, and NIH programs. Under the scope of the these programs, the synthesis of a limited series of analogs in order to improve the potencies and pharmacodynamic properties of the lead compound, where the core chemistry is either well established or less documented, were also undertaken. The remaining 10% of the work has originated other NCI, NIH programs. The purity and identity of all resynthesized compounds and intermediates were established by state-of-the-art physico-chemical methods. The quantities synthesized would vary from 200 mg to 100 grams. The overall objective of the contract will be the ¿Non-GMP¿ chemical synthesis of compounds of good purity needed for the cancer NExT program, and compounds arising from recommendation of the Biological Evaluation Committee. The new contract will be utilized for the purpose of synthesis of active single compound leads and their analogs using parallel synthesis methodology, as sometimes required by the NCI programs.

ARRA基金的增加将用于文献中已知的抗癌剂的合成和获得;这些可以在NCI的抗癌计划中进一步研究。 开发治疗学计划（DTP）的使命是开发新型合成和表征的天然产物作为潜在的抗癌剂。为了实现这一使命，该合同将致力于合成癌症治疗和诊断部（DCTD）和NIH其他部门的各种计划所需的小分子。该合同将为药物开发计划的早期阶段提供必要的合成支持。指定用于合成的小分子包括多种结构类别;例如，碳环化合物、杂环化合物、类固醇类似物和天然产物。它们起源于DCTD的NExT倡议，生物评价委员会（BEC）和其他NCI和NIH计划。在这些项目的范围内，还进行了有限系列类似物的合成，以改善先导化合物的效价和药效学特性，其中核心化学已充分确立或记录较少。其余10%的工作来自其他NCI，NIH项目。所有再合成化合物和中间体的纯度和鉴别均通过最先进的物理化学方法确定。合成的量从200毫克到100克不等。该合同的总体目标将是癌症NExT计划所需的高纯度化合物以及生物评估委员会推荐的化合物的“非GMP”化学合成。新合同将用于使用平行合成方法合成活性单一化合物先导化合物及其类似物，这有时是NCI计划所要求的。